Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 1.00 |
| ▸ | HPGD | P15428 | 7/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 1.00 |
| ▸ | GAA | P10253 | 6/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | ACHE | P22303 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | SI | P14410 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 7/20 | 0.42 |
| ▸ | CA12 | O43570 | 5/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.41 |
| ▸ | GLA | P06280 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Obliquin SCHEMBL12062102 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| Obliquin SCHEMBL29534204 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL6664850 | 0.77 | ALDH1A1 (0.63) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL6664851 | 0.77 | ALDH1A1 (0.63) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL12075314 | 0.77 | KDM4E (0.65) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL14492724 | 0.77 | ALDH1A1 (0.62) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL13464094 | 0.77 | ALDH1A1 (0.62) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| Dihydro-Obliquin SCHEMBL12062091 | 0.76 | ALDH1A1 (1.00) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| Ayapin SCHEMBL6694210 | 0.72 | KDM4E (0.57) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| Ayapin SCHEMBL30171405 | 0.72 | KDM4E (0.57) | KDM4EALDH1A1HPGDHSD17B10GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044094-B2 | Agents for preventing and treating disorders connected to impaired neurotransmission | DSM IP ASSETS B.V. (NL) | 2011-10-25 | — | — | US | claimed |
| EP-1802298-B1 | NOVEL AGENTS FOR PREVENTING AND TREATING DISORDERS CONNECTED TO IMPAIRED NEUROTRANSMISSION | DSM IP ASSETS BV (NL) | 2008-12-31 | — | — | EP | claimed |
| US-20070293563-A1 | Novel Agents for Preventing and Treating Disorders Connected to Impaired Neurotransmission | DSM IP ASSETS B.V. (NL) | 2007-12-20 | — | — | US | claimed |
| CN-101043886-A | Novel agents for the prevention and treatment of disorders associated with impaired neurotransmission | DSM IP ASSETS BV (NL) | 2007-09-26 | — | — | CN | claimed |
| EP-1802298-A2 | NOVEL AGENTS FOR PREVENTING AND TREATING DISORDERS CONNECTED TO IMPAIRED NEUROTRANSMISSION | DSMIP Assets B.V. (NL) | 2007-07-04 | — | — | EP | claimed |
| WO-2006042441-A2 | NOVEL AGENTS FOR PREVENTING AND TREATING DISORDERS CONNECTED TO IMPAIRED NEUROTRANSMISSION | DSM IP ASSETS B.V. (NL) | 2006-04-27 | — | — | WO | claimed |
| US-20180042899-A1 | Method of Treating Transplant Rejection and Autoimmune Diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-02-15 | — | — | US | disclosed |
| US-8772252-B2 | Coumarin compounds as melanogenesis modifiers and uses thereof | NEW YORK UNIVERSITY (US) | 2014-07-08 | — | — | US | disclosed |
| US-20140050694-A1 | Method of Treating Transplant Rejection and Autoimmune Diseases | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-02-20 | — | — | US | disclosed |
| US-8563754-B2 | Compounds, compositions and methods for preventing skin darkening | NEW YORK UNIVERSITY (US) | 2013-10-22 | — | — | US | disclosed |
| US-20120220545-A1 | COUMARIN COMPOUNDS AS MELANOGENESIS MODIFIERS AND USES THEREOF | NEW YORK UNIVERSITY | 2012-08-30 | — | — | US | disclosed |
| US-8044094-B2 | Agents for preventing and treating disorders connected to impaired neurotransmission | DSM IP ASSETS B.V. (NL) | 2011-10-25 | — | — | US | disclosed |
| US-8044094-B2 | Agents for preventing and treating disorders connected to impaired neurotransmission | DSM IP ASSETS B.V. (NL) | 2011-10-25 | — | — | US | disclosed |
| EP-1802298-A2 | NOVEL AGENTS FOR PREVENTING AND TREATING DISORDERS CONNECTED TO IMPAIRED NEUROTRANSMISSION | DSMIP Assets B.V. (NL) | 2007-07-04 | — | — | EP | disclosed |
| EP-1802298-A2 | NOVEL AGENTS FOR PREVENTING AND TREATING DISORDERS CONNECTED TO IMPAIRED NEUROTRANSMISSION | DSMIP Assets B.V. (NL) | 2007-07-04 | — | — | EP | disclosed |
| EP-1792623-A1 | Use of extracts and constituents of leontopodium as enhancers of cholinergic function | Leopold-Franzens-Universität Innsbruck (AT) | 2007-06-06 | — | — | EP | disclosed |
| WO-2007006492-A1 | USE OF EXTRACTS AND CONSTITUENTS OF LEONTOPODIUM AS ENHANCERS OF CHOLINERGIC FUNCTION | LEOPOLD-FRANZENS-UNIVERSITÄT INNSBRUCK (AT) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006042441-A3 | NOVEL AGENTS FOR PREVENTING AND TREATING DISORDERS CONNECTED TO IMPAIRED NEUROTRANSMISSION | DSM IP ASSETS BV (NL) | 2006-07-13 | — | — | WO | disclosed |
| WO-2006042441-A2 | NOVEL AGENTS FOR PREVENTING AND TREATING DISORDERS CONNECTED TO IMPAIRED NEUROTRANSMISSION | DSM IP ASSETS B.V. (NL) | 2006-04-27 | — | — | WO | disclosed |
| WO-2006042441-A2 | NOVEL AGENTS FOR PREVENTING AND TREATING DISORDERS CONNECTED TO IMPAIRED NEUROTRANSMISSION | DSM IP ASSETS B.V. (NL) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293563-A1 | Novel Agents for Preventing and Treating Disorders Connected to Impaired Neurotransmission | CHRNA2, CHRM1, CHRM5 | KDM4E 2225/4885ALDH1A1 757/4885HPGD 743/4885 |
| US-20120220545-A1 | COUMARIN COMPOUNDS AS MELANOGENESIS MODIFIERS AND USES THEREOF | TYR, MC1R, MITF | KDM4E 79/4885ALDH1A1 246/4885HPGD 2055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.